DE122011100062I1 - Phosphonatderivate eines glykopeptides. - Google Patents

Phosphonatderivate eines glykopeptides.

Info

Publication number
DE122011100062I1
DE122011100062I1 DE201112100062 DE122011100062C DE122011100062I1 DE 122011100062 I1 DE122011100062 I1 DE 122011100062I1 DE 201112100062 DE201112100062 DE 201112100062 DE 122011100062 C DE122011100062 C DE 122011100062C DE 122011100062 I1 DE122011100062 I1 DE 122011100062I1
Authority
DE
Germany
Prior art keywords
glycopeptide
phosphonate derivatives
phosphonate
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE201112100062
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Innoviva Inc
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of DE122011100062I1 publication Critical patent/DE122011100062I1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
DE201112100062 2000-06-22 2011-11-30 Phosphonatderivate eines glykopeptides. Pending DE122011100062I1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21341000P 2000-06-22 2000-06-22
PCT/US2001/013998 WO2001098328A2 (en) 2000-06-22 2001-05-01 Glycopeptide phosphonate derivatives

Publications (1)

Publication Number Publication Date
DE122011100062I1 true DE122011100062I1 (de) 2012-03-15

Family

ID=22795013

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60122516T Expired - Lifetime DE60122516T2 (de) 2000-06-22 2001-05-01 Phosphonatderivate eines glykopeptides
DE201112100062 Pending DE122011100062I1 (de) 2000-06-22 2011-11-30 Phosphonatderivate eines glykopeptides.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60122516T Expired - Lifetime DE60122516T2 (de) 2000-06-22 2001-05-01 Phosphonatderivate eines glykopeptides

Country Status (36)

Country Link
US (10) US6635618B2 (de)
EP (1) EP1292612B1 (de)
JP (2) JP3900491B2 (de)
KR (1) KR100768488B1 (de)
CN (1) CN100469788C (de)
AR (1) AR035333A1 (de)
AT (1) ATE337334T1 (de)
AU (2) AU2001261107B2 (de)
BR (1) BRPI0111222B8 (de)
CA (2) CA2411590C (de)
CY (2) CY1105194T1 (de)
CZ (1) CZ303672B6 (de)
DE (2) DE60122516T2 (de)
DK (1) DK1292612T3 (de)
EA (1) EA005953B1 (de)
EG (1) EG26726A (de)
ES (1) ES2271012T3 (de)
HK (1) HK1052191B (de)
HR (1) HRP20020888B1 (de)
HU (2) HU229370B1 (de)
IL (1) IL152408A (de)
IS (1) IS2303B (de)
LU (1) LU91908I2 (de)
MX (1) MXPA02012745A (de)
MY (1) MY127081A (de)
NO (2) NO330360B1 (de)
NZ (1) NZ522279A (de)
PL (1) PL207101B1 (de)
PT (1) PT1292612E (de)
RS (1) RS50499B (de)
SI (1) SI1292612T1 (de)
SK (1) SK287470B6 (de)
TW (1) TWI305209B (de)
UA (1) UA75083C2 (de)
WO (1) WO2001098328A2 (de)
ZA (1) ZA200209419B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ508594A (en) * 1998-12-23 2003-05-30 Theravance Inc Glycopeptide derivatives and pharmaceutical compositions containing the same
WO2001082971A2 (en) 2000-05-02 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
TWI275594B (en) 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI312785B (en) * 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives
AU2003231833A1 (en) * 2002-05-24 2003-12-12 Theravance, Inc. Cross-linked glycopeptide-cephalosporin antibiotics
US6951963B2 (en) 2002-06-17 2005-10-04 Theravance, Inc. Process for preparing N-protected β-amino aldehyde compounds
JP2006528704A (ja) * 2003-05-27 2006-12-21 セラヴァンス インコーポレーテッド グリコペプチド抗細菌剤と組み合わせたポリエンマクロライド抗真菌剤の使用
US7452861B2 (en) 2003-07-22 2008-11-18 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
WO2007082206A2 (en) * 2006-01-10 2007-07-19 Yu Ruey J N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use
JP2008112847A (ja) * 2006-10-30 2008-05-15 Shin Etsu Chem Co Ltd 単結晶シリコン太陽電池の製造方法及び単結晶シリコン太陽電池
WO2008077241A1 (en) 2006-12-22 2008-07-03 Targanta Therapeutics, Inc. Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
US20090069219A1 (en) * 2007-09-09 2009-03-12 Protia, Llc Deuterium-enriched telavancin
JP5620272B2 (ja) * 2007-11-09 2014-11-05 プロノヴァ・バイオファーマ・ノルゲ・アーエスＰｒｏｎｏｖａ ＢｉｏＰｈａｒｍａ ＮｏｒｇｅＡＳ 化粧品において，食品サプリメントとして，または医薬品として用いるための脂質化合物
JP2011507959A (ja) * 2007-12-26 2011-03-10 レアド トヘラペウトイクス，インコーポレーテッド 抗菌薬としての新規半合成糖ペプチド
EP2147910A1 (de) 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Neue Lipid-Verbindungen
US20100105607A1 (en) * 2008-10-24 2010-04-29 Lead Therapeutics, Inc. Novel semi-synthetic glycopeptides as antibacterial agents
GB2465863A (en) * 2008-12-05 2010-06-09 Lead Therapeutics Inc Semi-synthetic heptapeptidic glycopeptides for the treatment of bacterial infections
JP2012525391A (ja) 2009-04-28 2012-10-22 ターガンタ セラピューティクス コーポレイション オリタバンシンを用いた細菌感染の治療方法
PT2427415T (pt) 2009-05-08 2019-05-31 Basf As Ácidos gordos polinsaturados para o tratamento de doenças relacionadas com as áreas cardiovascular, metabólica e de doença inflamatória
WO2011005959A1 (en) 2009-07-09 2011-01-13 Plus Chemicals Sa Process for the preparation of n-protected-decylaminoethanal
KR102265409B1 (ko) 2010-11-05 2021-06-16 바스프 에이에스 지질 화합물을 이용한 치료방법
WO2013034675A1 (en) 2011-09-09 2013-03-14 Sandoz Ag Process for the synthesis of telavancin and its pharmaceutically acceptable salts as well as n-protected derivatives thereof
WO2013034676A1 (en) 2011-09-09 2013-03-14 Sandoz Ag Process for the synthesis of telavancin, its pharmaceutically acceptable salts as well as an n-protected imine-derivative of telavancin
JP5724937B2 (ja) * 2012-04-23 2015-05-27 ニプロ株式会社 腎臓集積性を示すペプチド、製剤
CN103897040B (zh) * 2012-12-27 2018-05-22 浙江医药股份有限公司新昌制药厂 新型糖肽类化合物或其药用盐及其制备方法、以及药物组合物和用途
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
CN105085636B (zh) * 2014-05-19 2020-05-01 中国医学科学院药物研究所 一类万古霉素衍生物、其制备方法及其在抗菌方面的应用
JP2018505910A (ja) 2015-02-23 2018-03-01 セラヴァンス バイオファーマ アンチバイオティクス アイピー， エルエルシー テラバンシンを投与するための用量および方法
AU2016256552B2 (en) 2015-04-28 2021-04-01 Pronova Biopharma Norge As Use of structurally enhanced fatty acids containing sulphur for preventing and/or treating non-alcoholic steatohepatitis
CN106188243B (zh) * 2015-05-05 2020-06-26 博瑞生物医药（苏州）股份有限公司 一种奥利万星的制备方法
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
EA201892413A1 (ru) 2016-05-09 2019-05-31 Кселлия Фармасьютикалз Апс Стабилизированные препараты гликопептидного антибиотика
EP3630154A4 (de) * 2017-05-22 2021-03-10 Insmed Incorporated Lipo-glycopeptidspaltbare derivate und verwendungen davon
CN107629116B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107629115B (zh) * 2017-09-08 2021-05-07 福建省微生物研究所 一种特拉万星的纯化方法
CN107987131B (zh) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的化合物、其制备方法和应用
US11925614B2 (en) 2017-12-06 2024-03-12 Basf As Fatty acid derivatives for treating non-alcoholic steatohepatitis
CN108409837B (zh) * 2018-03-06 2021-09-24 上海来益生物药物研究开发中心有限责任公司 一组具有抗耐药性细菌活性的糖肽类化合物、其制备方法和应用
JP2022507357A (ja) * 2018-11-21 2022-01-18 インスメッド インコーポレイテッド リポグリコペプチドクリーバブル誘導体およびそれらの使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6872A (en) * 1849-11-13 Means of changing the combination in bevolving tumbler-locks
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US4885275A (en) * 1987-10-15 1989-12-05 Eli Lilly And Company Vancomycin-HCL solutions and the lyophilization thereof
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
ZA909847B (en) * 1989-12-13 1992-08-26 Lilly Co Eli Glycopeptide derivatives
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5217493A (en) * 1992-03-11 1993-06-08 Board Of Regents, The University Of Texas System Antibacterial coated medical implants
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
JPH08503951A (ja) 1992-12-02 1996-04-30 インサイト・ビジョン・インコーポレイテッド シクロデキストリンとポリマーを用いた薬剤供給系
US6077822A (en) * 1993-09-14 2000-06-20 Dumex-Alpharma A/S Drug salts
PE40996A1 (es) 1994-01-28 1996-10-14 Lilly Co Eli Derivado de antibiotico de glucopeptido
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
US5614615A (en) 1995-03-21 1997-03-25 The Scripps Research Institute Sialyl Lewis X mimetics incorporating fucopeptides
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
US6391851B1 (en) * 1997-03-10 2002-05-21 Fujisawa Pharmaceutical Co., Ltd. Hydrochlorides of vancomycin antibiotics and process for producing the same
US5916873A (en) 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US6323176B1 (en) * 1998-02-25 2001-11-27 Eli Lilly And Company Cyclic peptide antifungal agents
WO2000004044A1 (en) * 1998-07-14 2000-01-27 Princeton University Glycopeptide antibiotics, combinatorial libraries of glycopeptide antibiotics and methods of producing same
NZ508594A (en) * 1998-12-23 2003-05-30 Theravance Inc Glycopeptide derivatives and pharmaceutical compositions containing the same
DE19911097A1 (de) 1999-03-12 2000-09-14 Basf Ag Verfahren zur Herstellung von festen cyclodextrinhaltigen Dosierungsformen
AU4054900A (en) 1999-04-02 2000-10-23 Advanced Medicine East, Inc. Desleucyl glycopeptide antibiotics and methods of making same
JP2000302687A (ja) 1999-04-22 2000-10-31 Sagami Chem Res Center 抗菌性オリゴマー及び抗菌剤
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
WO2001082971A2 (en) 2000-05-02 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
EP2263654B1 (de) 2000-06-21 2012-10-10 Cubist Pharmaceuticals, Inc. Arzneizusammensetzungen zum Verbessern der oralen Absorption von antimikrobiellen Wirkstoffen
WO2001098326A2 (en) 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
UA75083C2 (uk) * 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
ES2302733T3 (es) 2000-06-22 2008-08-01 Theravance, Inc. Derivados carboxi-sacaridos de glucopeptido.
WO2001098329A1 (en) 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
TWI275594B (en) * 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
TWI233932B (en) * 2001-08-24 2005-06-11 Theravance Inc Process for purifying glycopeptide phosphonate derivatives

Also Published As

Publication number Publication date
BRPI0111222B8 (pt) 2021-05-25
MY127081A (en) 2006-11-30
US8859506B2 (en) 2014-10-14
HRP20020888B1 (en) 2007-12-31
ZA200209419B (en) 2004-02-19
UA75083C2 (uk) 2006-03-15
EA200300050A1 (ru) 2003-04-24
ATE337334T1 (de) 2006-09-15
CN1437611A (zh) 2003-08-20
US20120283195A1 (en) 2012-11-08
NO2011025I1 (no) 2011-11-18
US20030207797A1 (en) 2003-11-06
IS6600A (is) 2002-10-29
SK287470B6 (sk) 2010-10-07
CA2411590A1 (en) 2001-12-27
NZ522279A (en) 2004-07-30
HUP0301320A3 (en) 2007-05-29
EA005953B1 (ru) 2005-08-25
BR0111222A (pt) 2003-04-01
PT1292612E (pt) 2006-12-29
KR20030032970A (ko) 2003-04-26
US6872701B2 (en) 2005-03-29
US8101575B2 (en) 2012-01-24
HU229370B1 (hu) 2013-11-28
NO20025954D0 (no) 2002-12-11
CY2012006I2 (el) 2016-06-22
EP1292612A2 (de) 2003-03-19
US20140024604A1 (en) 2014-01-23
DE60122516T2 (de) 2007-01-04
IS2303B (is) 2007-10-15
CY1105194T1 (el) 2010-03-03
EG26726A (en) 2014-06-18
US6887976B2 (en) 2005-05-03
CZ20023942A3 (cs) 2003-03-12
HUS1400024I1 (hu) 2017-03-28
NO20025954L (no) 2002-12-11
DK1292612T3 (da) 2007-01-02
EP1292612B1 (de) 2006-08-23
NO2011025I2 (de) 2011-11-18
ES2271012T3 (es) 2007-04-16
MXPA02012745A (es) 2004-04-05
KR100768488B1 (ko) 2007-10-18
US20060063706A1 (en) 2006-03-23
HUP0301320A2 (hu) 2003-08-28
US7700550B2 (en) 2010-04-20
SK18522002A3 (sk) 2003-06-03
HK1052191A1 (en) 2003-09-05
CA2713965A1 (en) 2001-12-27
BRPI0111222B1 (pt) 2015-03-17
US20020022590A1 (en) 2002-02-21
CA2411590C (en) 2010-10-19
AR035333A1 (es) 2004-05-12
RS50499B (sr) 2010-03-02
JP2007045842A (ja) 2007-02-22
AU6110701A (en) 2002-01-02
US7351691B2 (en) 2008-04-01
US20040063916A1 (en) 2004-04-01
JP3900491B2 (ja) 2007-04-04
US6635618B2 (en) 2003-10-21
US8541375B2 (en) 2013-09-24
US7208471B2 (en) 2007-04-24
SI1292612T1 (sl) 2006-12-31
PL359419A1 (en) 2004-08-23
DE60122516D1 (de) 2006-10-05
LU91908I2 (fr) 2012-01-30
JP2004501161A (ja) 2004-01-15
US20100160211A1 (en) 2010-06-24
CY2012006I1 (el) 2016-06-22
YU96902A (sh) 2006-01-16
US7008923B2 (en) 2006-03-07
WO2001098328A3 (en) 2002-04-11
PL207101B1 (pl) 2010-11-30
HRP20020888A2 (en) 2005-02-28
CN100469788C (zh) 2009-03-18
IL152408A (en) 2009-05-04
AU2001261107B2 (en) 2006-07-20
NO330360B1 (no) 2011-04-04
TWI305209B (en) 2009-01-11
IL152408A0 (en) 2003-05-29
US20080312407A1 (en) 2008-12-18
CZ303672B6 (cs) 2013-02-20
US20070049519A1 (en) 2007-03-01
US20050164916A1 (en) 2005-07-28
HK1052191B (zh) 2007-01-26
WO2001098328A2 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
DE122011100062I1 (de) Phosphonatderivate eines glykopeptides.
NO20025978L (no) Benzotiazol-derivater
NO20010760D0 (no) Gripeanordning for brönntraktor
ATE271031T1 (de) Neue phenylpropargyletherderivate
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
DE60044829D1 (de) Chromenverbindung
ATE288437T1 (de) Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1280809T3 (da) Antitumorecteinascidinderivater
ATE334114T1 (de) Substituierte c-cyclohexylmethylamin-derivate
DE50107988D1 (de) Substituierte 1,2,3,4-tetrahydrochinolin-2-carbonsäurederivate
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
DE60111268D1 (de) Neue pleuromutilinderivate
AR028607A1 (es) Derivados de 1,4-diazepan-2,5-diona
DE60133976D1 (de) Turbomaschinen
ATE265422T1 (de) Neue phenylheteroalkylamin-derivate
DK1246791T3 (da) Aminomethyl-phenyl-cyklohexanonderivater
DZ3344A1 (fr) Derives de sulfonamide
ATE293126T1 (de) Cyclische hexapeptidderivate
DZ3343A1 (fr) Derives de sulfonamide
DK1322590T3 (da) Substituerede 5-amino-1-penten-3-ol-derivater
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
NO20000222D0 (no) Munnstykke for mudringsarm
ITPG20000060A1 (it) Ali - aumento aderenza per mto
DK1259535T3 (da) Cykliske hexapeptidderivater